Published • loading... • Updated
FDA Approves Lumvoa for Thyroid Eye Disease
The therapy offers a shorter infusion course and immediate U.S. availability, while Viridian management is tempering near-term revenue expectations.
Summary by Healio
2 Articles
2 Articles
FDA approves Lumvoa for thyroid eye disease
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics. The approval was supported by data from the phase 3 THRIVE and THRIVE-2 pivotal clinical trials, which investigated Lumvoa (veligrotug-vvze, 500 mg) for active and chronic thyroid eye disease (TED), respectively. In
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources2
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
